Last Updated: 17 Sep 2024
Executive Summary
Immunic Inc. (IMUX) is a clinical-stage biopharmaceutical company developing oral immunology therapies for chronic autoimmune and inflammatory diseases. The company has a market capitalization of $136.92 million and trades on the NASDAQ exchange.
Company Overview
Immunic's pipeline includes IMU-838, an oral selective TYK2 inhibitor for the treatment of moderate-to-severe psoriasis and atopic dermatitis; IMU-935, an oral selective JAK1 inhibitor for the treatment of alopecia areata; and IMU-856, an oral selective BTK inhibitor for the treatment of autoimmune diseases.
Fundamental Analysis
Immunic's financial performance has been weak in recent quarters. The company reported a net loss of $93.53 million in the latest quarter, with no revenue. The company has a negative EBITDA of $93.53 million and a negative return on assets of -0.668%.
Technical Analysis
IMUX's stock price has been trading within a range of $0.945 to $1.92 over the past 52 weeks. The stock is currently trading at $1.6, above its 50-day and 200-day moving averages.
Short Term Outlook
IMUX's stock price is expected to remain range-bound in the short term. The company's financial performance has been weak, and there are no major catalysts on the horizon.
Long Term Outlook
IMUX's long-term outlook is more positive. The company's pipeline has the potential to generate significant revenue if IMU-838, IMU-935, and IMU-856 are successful in clinical trials.
Analyst Recommendations
Analysts are mixed on IMUX. One analyst has a Strong Buy rating, two have Buy ratings, and one has a Hold rating. The average analyst target price is $11.9.
